Skip to content
DataLookout
Menu

NCT06253871

A Phase 1/2 Study of IAM1363 in HER2 Cancers

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)

At risk: Primary completion moved at least 9 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 14 versions: 13 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 2027 to Oct 2028 Show 9 more changesShow less
    • Phase changed: Phase 1 → Phase 1/2
    • Eligibility criteria expanded, about 11 words
    • Enrollment increased: 383 → 463 participants
    • Interventions modified
    • Trial arms changed: 1 → 4
    • Secondary endpoints: details revised at 6 of 6 entries
    • Site details revised at 6 of 53 sites
    • Study title revised
    • Study description shortened, about 4 words
  2. Minor Site contacts updated at 1 of 53 sitesv13
  3. Minor Trial sites expanded: 48 → 53 locationsv12
  4. Notable Primary completion pushed from Mar 2027 to Dec 2027v11 Show 7 more changesShow less
    • Primary endpoint(s) modified
    • Enrollment increased: 243 → 383 participants
    • Eligibility criteria expanded, about 39 words
    • Trial sites expanded: 45 → 48 locations
    • Study completion pushed from Mar 2028 to Dec 2028
    • Secondary endpoints: 14 to 6
    • Study description expanded, about 14 words
  5. Minor Study sites: 39 to 45v10
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Study sites: 28 to 39v9
  2. Minor Study sites: 12 to 28v8
  3. Notable Primary completion date: Apr 2028 to Mar 2027v7 Show 8 more changesShow less
    • Primary endpoints: 4 to 7
    • Eligibility criteria expanded, about 1 word
    • Enrollment target: 287 to 243
    • Study completion date: Apr 2028 to Mar 2028
    • Interventions: IAM1363 (Drug), Trastuzumab (Drug) to IAM1363 (Drug)
    • Secondary endpoints: 11 to 14
    • Study description shortened, about 29 words
    • Study arms: 2 to 1
  4. Minor Study sites: 9 to 12v6
  5. Minor Study sites: 4 to 9v5
  6. Minor Study sites: 1 to 4v4
  7. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Feb 2024 to Mar 25, 2024
    • Site details revised
    v3
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence and severity of dose limiting toxicities (DLTs) (Part 1 only)
Timeframe: 21 days
Incidence and severity of adverse events (AEs)
Timeframe: Through 30 days after the last dose of study drug (up to 90 days for Cohort 4D)
Pharmacokinetic (PK) parameters
Timeframe: Up to 42 days
Confirmed objective response rate (cORR)
Timeframe: Through study completion, estimated as 57 months
Confirmed central nervous system ORR (CNS-cORR)
Timeframe: Through study completion, estimated as 57 months
Frequency of IAM1363 dose modifications, including treatment discontinuations
Timeframe: Through 30 days after the last dose of study drug
Incidence and severity of clinical laboratory abnormalities
Timeframe: Through 30 days post last dose of study drug
Incidence of ECG abnormalities
Timeframe: Through 30 days after the last dose of study drug

Secondary (6)

Best overall response (BoR) rate
Duration of response (DoR)
Disease control rate (DCR)
Clinical benefit rate (CBR)
Progression-free survival (PFS)
Show 1 moreShow less
Overall survival (OS)

Arms and interventions

Part 1: Monotherapy Dose-escalationExperimental

Oral treatment with IAM1363 capsules, administered in increasing dose levels starting at 120 mg QD in 21-day cycles.

Part 2: Monotherapy Dose OptimizationExperimental

Oral treatment with IAM1363 capsules, administered in 21-day cycles. Participants randomized to receive either 960 mg QD or 1200 mg QD.

Part 3: Monotherapy Dose ExpansionExperimental

Oral treatment with IAM1363 capsules or tablets, administered in up to 5 cohorts at 960 mg QD in 21-day cycles.

Part 4: Combination CohortsExperimental

Oral treatment with IAM1363 capsules or tablets, administered in combination with either capecitabine + trastuzumab (HER2+ metastatic breast cancer), capecitabine + zanidatamab (HER2+ metastatic breast cancer), T-Dxd (HER2+ gastroesophageal adenocarcinoma), and pembrolizumab +/- carboplatin +/- pemetrexed (HER2 amplified or overexpressing non-squamous NSCLC) in 14 or 21-day cycles.

Drugs: IAM1363, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + trastuzumab, Oral treatment with IAM1363 capsules or tablets, administered in combination with capecitabine + zanidatamab, Oral treatment with IAM1363 capsules or tablets, administered in combination with T-Dxd, Oral treatment with IAM1363 capsules or tablets, administered in combination with pembrolizumab +/- carboplatin +/- pemetrexed

Sites

53 sites in 8 countries

United States 29, Spain 6, Italy 4, South Korea 4, France 3, Ireland 3, United Kingdom 3, Netherlands 1